March 25, 2008 - Data on the MitraClip, a device that just received CE Mark approval and is designed to nonsurgically treat the effects of mitral regurgitation (ischemic and cardiomyopathy), will be presented at the SCAI-ACCi2 annual meeting in Chicago as part of the late-breaking clinical trial program on Tuesday, April 1.
James Hermiller, M.D., director of the interventional fellowship program at St. Vincent Heart Center of Indiana in Indianapolis, IN, will make the presentation.
Evalve Inc., the manufacturer of the MitraClip system, recently completed enrollment in the high-risk registry arm of the Endovascular Valve Edge-to-Edge REpair STudy (EVEREST) in North America. Patients who are high-risk surgical candidates may benefit from a less invasive procedure. Investigators are collecting follow-up data to assess the risk-benefit profile from the less invasive percutaneous intervention with the MitraClip device.
The EVEREST investigators from more than 40 sites across North America have treated more than 300 patients with close to 400 MitraClip devices implanted. Trial data continues to grow with three-year follow up results available as well as four-year data from some patients.
For more information: www.scai-acci2.org and www.evalveinc.com